Expression of RXR-α and RXR-β subunits before therapy and after relapse of disease. Western blot analysis of protein extracts from patient PBMCs collected at day 0 before therapy and day 180 after initiating therapy revealed marked down-regulation of RXR-α protein after bexarotene therapy. Expression of both proteins was normalized to β-actin.